10.34
+21.22%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biodesix
From its filings with the US Securities and Exchange Commission
Biodesix is based in Louisville, Colorado and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BDSX. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $88.5m and a net loss of $35.3m. At that date it held total assets of $87.5m and shareholders' equity of −$2.5m. By business, Diagnostic tests. brought in 89.5% of revenue, followed by Development Services [Member] at 10.5%.
Biodesix, Inc. (“Biodesix”, “we,” “us,” “our” or the “Company”) is a leading diagnostic solutions company. Our mission at Biodesix is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible, and address immediate clinical needs. We envision a world where patient disease is conquered through the guidance of personalized diagnostics.
We derive our revenue from two sources: (i) Biodesix Lung Diagnostic Testing (Lung Diagnostic Testing), providing lung diagnostic testing services for healthcare providers associated with our five blood-based tests and (ii) Biodesix Development Services (Development Services) providing diagnostic testing services and consulting to biopharmaceutical, life sciences, and diagnostic companies.
At Biodesix, we have built a team with deep experience in diagnostics including commercialization, reimbursement, regulatory, medical affairs, research and development, technology, and operations to provide needed products and services to address critical clinical questions and help improve patient care. We believe that establishing a new standard of care utilizing personalized diagnostics requires an extensive understanding of clinical needs, scientific expertise to develop tests using the optimal technology for each clinical question, development of clinical evidence to demonstrate benefits of the testing, a scalable operational infrastructure, and an established commercial channel to drive market adoption and payer coverage.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 28 Oct 2020
- Employees
- 245
- Website
- biodesix.com ↗
- Head office
- 919 WEST DILLON ROAD, LOUISVILLE, CO, 80027
- Incorporated in
- DE
- Classification
- Services-Medical Laboratories
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. John PatienceIndependent Chairman of the Board$306,394
- Mr. Scott HuttonPresident, Chief Executive Officer, Director, since 2018$2.1m
- Ms. Robin CowieChief Financial Officer, Treasurer, Secretary, since 2020$875,536
- Mr. Kieran O'KaneChief Commercial Officer$900,645
- Ms. Jean FranchiIndependent Director$328,499
- Dr. Jon KayyemIndependent Director$306,394
- Mr. Lawrence KennedyIndependent Director$306,394
- Mr. Hany MassaranyIndependent Director$322,973
- Dr. Matthew StrobeckIndependent Director$317,447
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 57
- Environment
- 63
- Social
- 56
- Governance
- 53
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biodesix offers Nodify XL2 and Nodify CDT blood-based lung cancer tests for clinical use.
- Biodesix provides GeneStrat and VeriStrat tests for lung disease diagnostics.
- Biodesix's SARS-CoV-2 tests include Bio-Rad ddPCR and Platelia Total Ab testing.
Weaknesses
- Biodesix's diagnostic services are limited to lung disease and coronavirus testing.
- Biodesix has only 245 employees, which may limit scalability.
- Biodesix's IPO was in 2020, indicating a relatively new market presence.
Opportunities
- Biodesix can expand its blood-based diagnostic services to other disease areas.
- Biodesix can leverage AI platform for new diagnostic solutions in lung disease.
- Biodesix can partner with biopharmaceutical companies for companion diagnostics development.
Threats
- Biodesix faces competition from other diagnostic companies in lung disease testing.
- Biodesix's reliance on blood-based tests may be challenged by emerging technologies.
- Biodesix's focus on lung disease could limit market growth potential.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.